European Commission Approves Viread ® for HIV-1 Infection in Children and Adolescents and for Chronic Hepatitis B in Adolescents

Nyheten uppdaterades 2012-11-29 15:39

New Oral Granule
Formulation and Lower-Strength for New Indications

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European
Commission has granted marketing authorization for two new indications for
once-daily ® (tenofovir disoproxil fumarate). The first new
indication permits the use of Viread…

Källa: Mynewsdesk news release

Lämna gärna en kommentar